MAPT and neurodegenerative disease: Monoclonal antibodies like MC-1, Alz50, TOMA1 and TOMA2 have been implicated for their promising potential for immunotherapy against soluble toxic conformations and tau oligomeric species; the most toxic tau species in neurodegenerative disease including AD.